Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: Final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up

Oral Oncology

Volumn 42, Issue 7, 2006, Pages 675-684

  Rapidis, Alexander D ^a   Trichas, Miltiades ^a   Stavrinidis, Elias ^a   Roupakia, Alexandra ^a   Ioannidou, Georgia ^a   Kritselis, George ^a   Liossi, Panaiyota ^a   Giannakouras, George ^a   Douzinas, Emmanuel E ^b   Katsilieris, Ioannis ^a  

^a SAINT SAVVAS HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

5 Fluorouracil; Cisplatin; Concurrent chemoradiation; Docetaxel; Head and neck carcinoma; Induction chemotherapy; Oral cancer; Oral squamous cell carcinoma; Radiochemotherapy

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; DIPHENHYDRAMINE; DOCETAXEL; ERYTHROPOIETIN; FLUOROURACIL; GRANISETRON; GRANULOCYTE COLONY STIMULATING FACTOR; METHYLPREDNISOLONE; RANITIDINE;

ADULT; ADVANCED CANCER; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DYSARTHRIA; DYSPHAGIA; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEAD AND NECK CARCINOMA; HEART INFARCTION; HOARSENESS; HUMAN; INFECTION; KARNOFSKY PERFORMANCE STATUS; LARYNX; MALE; METASTASIS; MOUTH; MUCOSA INFLAMMATION; MULTIVARIATE ANALYSIS; NAUSEA; NEUTROPENIA; ODYNOPHAGIA; ONYCHOLYSIS; ORGAN PRESERVATION; OROPHARYNX; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DERMATITIS; RADIATION DOSE; RADIATION DOSE FRACTIONATION; SKIN IRRITATION; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TONGUE; TREATMENT RESPONSE; VALIDATION PROCESS; WORLD HEALTH ORGANIZATION; XEROSTOMIA;

ADULT; AGE DISTRIBUTION; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIATION INJURIES; RADIOTHERAPY; REMISSION INDUCTION; SEX DISTRIBUTION; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 33746260363     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2005.12.006     Document Type: Article

References (76)

1. Vokes E.E., Weichselbaum R.R., Lippman S.M., and Hong W.K. Head and neck cancer. N Engl J Med 328 (1993) 184-194
2. Vokes E.E., and Weichselbaum R.R. Measurable impact: multi-modality therapy of head and neck cancer. Int J Radiat Oncol Biol Phys 27 (1993) 481-482
3. Dimery I.W., and Hong W.K. Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 85 (1993) 95-111
4. Munro A.J. An overview of randomized controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 71 (1995) 83-91
5. El-Sayed S., and Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials. J Clin Oncol 14 (1996) 838-847
6. Rinehart J., Ruff T., et al. Neoadjuvant and concomitant chemotherapy and radiation therapy in patients with advanced head and neck carcinoma. Otolaryngol Head Neck Surg 132 (2005) 69-74
7. Paccagnella A., Orlando A., Marchiori C., et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 86 (1994) 265-272
8. Lefebvre J.L., Chevalier D., Luboinski B., Kirkpatrick A., Collette L., and Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 88 (1996) 890-899
9. Guadagnolo B.A., Haddad R.I., Posner M.R., et al. Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal cancer. Am J Clin Oncol 28 (2005) 371-378
10. Forastiere A.A., Goepfert H., Maor M., et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349 (2003) 2091-2098
11. Merlano M., Corvo R., and Margarino G. Combined chemotherapy and radiation therapy in advanced inoperable squamous cell carcinoma of the head and neck. The final report of a randomized trial. Cancer 67 (1991) 915-921
12. Merlano M., Benasso M., Corvo R., et al. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst 88 (1996) 583-589
13. Adelstein D.J., Tan E.H., and Lavertu P. Treatment of head and neck cancer: the role of chemotherapy. Crit Rev Oncol Hematol 24 (1996) 97-116
14. Adelstein D.J., Saxton J.P., Lavertu P., et al. Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer with hyperfractionated radiation and concurrent chemotherapy. J Clin Oncol 20 (2002) 1405-1410
15. Kish J.A., Ensley J.F., Jacobs J., Weaver A., Cummings G., and Al-Sarraf M. A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. Cancer 56 (1985) 2740-2744
16. Kutter J., Ozsahin M., Monnier P., and Stupp R. Combined modality treatment with full-dose chemotherapy and concomitant boost radiotherapy for advanced head and neck carcinoma. Eur Arch Otorhinolaryngol 262 (2005) 1-7
17. Brockstein B., Haraf D.J., Rademaker A.W., et al. Patterns of failure, prognostic factors and survival in loco regionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol 15 (2004) 1179-1186
18. Schrijvers D., and Vermorken J.B. Update on the taxoids and other new agents in head and neck cancer therapy. Curr Opin Oncol 10 (1998) 233-241
19. Braakhuis B.J., Kegel A., and Welters M.J. The growth inhibiting effect of docetaxel (Taxotere) in head and neck squamous cell carcinoma xenografts. Cancer Lett 81 (1994) 151-154
20. Huttmann C., Eckardt A., Fokas K., and Haindl J. Experimental chemotherapy of xenotransplanted oral squamous epithelial carcinoma: effectiveness of docetaxel (taxotere) in the nude mouse model. Mund Kiefer Gesichtschir 3 (1999) 257-262
21. Pradier O., Rave-Frank M., Lehmann J., et al. Effects of docetaxel in combination with radiation on human head and neck cancer cells (ZMK-1) and cervical squamous cell carcinoma cells (CaSki). Int J Cancer 91 (2001) 840-845
22. Janinis J., Papadakou M., Panagos G., et al. Sequential chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced head and neck cancer. Am J Clin Oncol 24 (2001) 227-231
23. Couteau C., Chouaki N., Leyvraz S., et al. A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. Br J Cancer 81 (1999) 457-462
24. Schoffski P., Catimel G., Planting A.S., et al. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group. Ann Oncol 10 (1999) 119-122
25. Forastiere A.A., Shank D., Neuberg D., Taylor IV S.G., DeConti R.C., and Adams G. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer 82 (1998) 2270-2274
26. Forastiere A.A., Leong T., Rowinsky E., et al. Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J Clin Oncol 19 (2001) 1088-1095
27. Forastiere A.A. Is there a new role for induction chemotherapy in the treatment of head and neck cancer?. J Natl Cancer Inst 96 (2004) 1647-1649
28. Cooper J.S., Pajak T.F., Forastiere A.A., et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. J Engl J Med 350 (2004) 1937-1944
29. Colevas A.D., Busse P.M., Norris C.M., et al. Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial. J Clin Oncol 16 (1998) 1331-1339
30. Colevas A.D., Norris C.M., Tishler R.B., et al. Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol 17 (1999) 3503-3511
31. Mauer A.M., Masters G.A., Haraf D.J., et al. Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol 16 (1998) 159-164
32. Rapidis A.D., Stavrinidis E., Katsilieris I., et al. The efficacy of aggressive chemo-radiation in inoperable head and neck cancer. Preliminary results from a phase II study with docetaxel, cisplatin and 5-fluorouracil. Ann Oncol 13 Suppl. 5 (2002) 154
33. Rapidis A.D., Stavrinidis E., Trichas M., et al. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck. Results from a phase II study with docetaxel, cisplatin and 5-fluorouracil. Ann Oncol 15 Suppl. 3 (2004) 137
34. Pignon J.P., Bourhis J., Domenge C., and Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355 (2000) 949-955
35. Bourhis J., and Eschwege F. Radiotherapy-chemotherapy combinations in head and neck squamous cell carcinoma: overview of randomized trials. Anticancer Res 16 (1996) 2397-2402
36. Licitra L., and Vermorken J.B. Is there still a role for neoadjuvant chemotherapy in head and neck cancer?. Ann Oncol 15 (2004) 7-11
37. Bernier J., Domenge C., Ozsahin M., et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350 (2004) 1945-1952
38. Leon X., Lopez-Pousa A., de Vega M., Orus C., de Juan M., and Quer M. Results of an organ preservation protocol with induction chemotherapy andradiotherapy in patients with locally advanced laryngeal carcinoma. Eur Arch Otorhinolaryngol 262 (2005) 93-98
39. Lavertu P., Adelstein D.J., Saxton J.P., et al. Aggressive concurrent chemoradiotherapy for squamous cell head and neck cancer. Arch Otolaryngol Head neck Surg 125 (1999) 142-148
40. Koch W.M., Lee D.J., Eisele D.W., et al. Chemoradiotherapy for organ preservation in oral and pharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 121 (1995) 974-980
41. Pazdur R., Kudelka A.P., Kavanagh J.J., Cohen P.R., and Raber M.N. The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev 19 (1993) 351-386
42. Hesse K., Heinrich B., Zimmermann F., et al. Combined radiochemotherapy with docetaxel in patients with unresectable locally advanced head and neck tumors. Strahlenther Onkol 176 (2000) 67-72
43. Dreyfuss A.I., Clark J.R., Norris C.M., et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 14 (1996) 1672-1678
44. Schrijvers D., and Vermorken J.B. Role of taxoids in head and neck cancer. The Oncologist 5 (2000) 199-208
45. Schrijvers D., and Vermorken J.B. Taxanes in the treatment of head and neck cancer. Curr Opin Oncol 17 (2005) 218-224
46. Posner M.R., and Lefebvre J.L. Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck. Br J Cancer 88 (2003) 11-17
47. Tishler R.B., Norris Jr. C.M., Colevas A.D., et al. A phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck. Cancer 95 (2002) 1472-1481
48. Haddad R., Colevas A.D., Tishler R., et al. Doxetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck. The Dana Farber Cancer Institute Experience. Cancer 97 (2003) 412-418
49. Tai C.-J., Wang W.-S., Liu J.-H., et al. Salvage therapy with single-agent paclitaxel by 3-h infusion in metastatic breast cancer: an experience in Taipei Veterans General Hospital. Jpn J Clin Oncol 31 (2001) 477-481
50. Posner M.R., Glisson B., Frenette G., et al. Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol 19 (2001) 1096-1104
51. Baur M., Kienzer H.-R., Schweiger J., et al. Docetaxel/cisplatin as first-line chemotherapy in patients with head and neck carcinoma. A phase II trial. Cancer 94 (2002) 2953-2958
52. Kovacs A.F., Schiemann M., and Turowski B. Combined modality treatment of oral and oropharyngeal cancer including neoadjuvant intraarterial cisplatin and radical surgery followed by concurrent radiation and chemotherapy with weekly docebaxel - three year results of a pilot study. J Cranio-Maxillofac Surg 30 (2002) 112-120
53. Watanabe A., Taniguchi M., and Sasaki S. Induction chemotherapy with docetaxel, cisplatin, fluorouracil and /-leucovorin for locally advanced head and neck cancers: a modified regimen for Japanese patients. Anti-Cancer Drugs 14 (2003) 801-807
54. Khafif A., Canfield V.A., Syzek E.J., and Medina J.E. Results of a phase I-II trial of concomitant hyperfractionated radiation and oral etoposide (VR-16) in patients with unresectable squamous cell carcinoma of the head and neck. Am J Otolaryngol 24 (2003) 1-5
55. Haddad R.I., and Van Echo D.A. Phase II study of docetaxel and topotecan combination chemotherapy in patients with advanced head and neck cancer. Cancer Chemother Pharmacol 52 (2003) 303-306
56. Kovacs A.F., Mose S., Bottcher H.D., and Bitter K. Multimodality treatment including postoperative radiation and concurrent chemotherapy with weekly docetaxel is feasible and effective in patients with oral and oropharyngeal cancer. Strahlenther Onkol 181 (2005) 26-34
57. Haddad R., Tishler R.B., Norris C.M., et al. Docetaxel, cisplatin, 5-flurorouracil (TPF)-Based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment. The Oncologist 8 (2003) 35-44
58. Niwa H., Wentzel A.L., Li M., et al. Antitumor effects of epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck. Clin Cancer Res 9 (2003) 5028-5035
59. Suzuki M., Nishimura Y., Nakamatsu K., et al. Phase I study of weekly docetaxel infusion and concurrent radiation therapy for head and neck cancer. Jpn J Clin Oncol 33 (2003) 297-301
60. Schrijvers D., Van Herpen C., Kerger J., et al. Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study. Ann Oncol 15 (2004) 638-645
61. Kurita H., Yamamoto E., Nozaki S., Wada S., Furuta I., and Kurashina K. Multicenter phase I trial of induction chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma. Oral Oncol 40 (2004) 1000-1006
62. Hehr T., Classen J., Belka C., et al. Reirradiation alternating with docetaxel and cisplatin in inoperable recurrence of head-and-neck cancer: a prospective phase I/II trial. Int J Radiat Oncol Biol Phys 61 (2005) 1423-1431
63. Huang G.-C., Liu S.-Y., Lin M.-H., Kuo Y.-Y., and Liu Y.-C. The synergistic cytotoxicity of cisplatin and taxol in killing oral squamous cell carcinoma. Jpn J Clin Oncol 34 (2004) 499-504
64. Calais G., Bardet E., Sire C., et al. Radiotherapy with concomitant weekly docetaxel for stages III/IV oropharynx carcinoma. Results of the 98-02 GORTEC phase II trial. Int J Radiat Oncol Biol Phys 58 (2004) 161-166
65. Fujii M., Tsukuda M., Satake B., et al. Phase I/II trial of weekly docetaxel and concomitant radiotherapy for squamous cell carcinoma of the head and neck. Int J Clin Oncol 9 (2004) 107-112
66. Genet D., Cupissol D., Calais G., et al. Docetaxel plus-fluorouracil in locally recurrent and/or metastatic squamous cell carcinoma of the head and neck. A phase II multicenter study. Am J Clin Oncol 27 (2004) 472-476
67. Shibuya Y., Tanimoto H., Umeda M., Yokoo S., and Komori T. Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil for tongue cancer. Kobe J Med Sci 50 (2004) 1-7
68. Ghi M.G., Paccagnella A., D'Amanzo P., et al. Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study. Int J Radiat Oncol Biol Phys 59 (2004) 481-487
69. De Castro J., Lorenzo A., Morales S., et al. Phase II study of a fixed dose-rate infusion of gemcitabine associated with docetaxel in advanced non-small-cell lung carcinoma. Cancer Chemother Pharmacol 55 (2005) 197-202
70. Umeda M., Komatsubara H., Ojima Y., et al. Lack of survival advantage in patients with advanced, respectable squamous cell carcinoma of the oral cavity receiving induction chemotherapy with cisplatin (CDDP), docetaxel (TXT) and 5-fluorouracil (5-FU). Kobe J Med Sci 50 (2004) 189-196
71. Airoldi M., Cattel L., Cortesina G., et al. Docetaxel, carboplatin and concomitant radiotherapy for unresectable squamous cell carcinoma of the head and neck. Pharmacokinetic and clinical data of a phase I-II study. Am J Clin Oncol 27 (2004) 155-163
72. Teh B., Kobayashi W., Narita K., Fukui R., and Kimura H. Superselective docetaxel-nedaplatin combined infusion concurrent with radiation therapy in advanced oral cancers. Oral Oncol Extra 40 (2004) 126-131
73. Fonseca E., Grau J.J., Sastre J., et al. Induction chemotherapy with cisplatin/docetaxel versus cisplatin/5-fluorouracil for locally advanced squamous cell carcinoma of the head and neck: a randomized phase II study. Eur J Cancer 41 (2005) 1254-1260
74. Kramer N.M., Horwitz E.M., Cheng, et al. Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies. Head Neck 27 (2005) 406-414
75. Schwartz D.L., Montgomery R.B., Yueh B., et al. Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck. Cancer 103 (2005) 2534-2543
76. Vermorken J.B., Remenar E., van Herpen C., et al. Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): a phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971). J Clin Oncol 22 suppl. 14S (2004) 5508